Effects of topical antiglaucoma medications on the ocular surface

Ocular Surface

Volumn 3, Issue 1, 2005, Pages 27-40

  Asbell, Penny A ^a   Potapova, Natalia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse effects of drugs; Antiglaucoma eye drops; Decreased tear function; Drug preservatives; Inflammation; Ocular toxicity; Squamous cell metaplasia; Superficial punctate keratitis; Topical antiglaucoma medications

Indexed keywords

ADRENALIN; ALPHAGAN P; ANTIGLAUCOMA AGENT; BETAXOLOL; BETOPTIC S; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CYTOKINE; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; DRUG PRESERVATIVE; EYE DROPS; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; LATANOPROST; LEVOBUNOLOL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PILOCARPINE; PROSTAGLANDIN F2 ALPHA; TIMOLOL; TIMOLOL MALEATE; UNOPROSTONE ISOPROPYL ESTER;

ARTICLE; BURNING SENSATION; CELL STRUCTURE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONJUNCTIVAL HYPEREMIA; CORNEA DISEASE; CYTOLOGY; DISEASE MARKER; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRY EYE; EYE DISEASE; EYE IRRITATION; FILTERING OPERATION; GLAUCOMA; HUMAN; INFLAMMATION; INTRAOCULAR FOREIGN BODY; LACRIMAL DUCT; NONHUMAN; PATIENT COMPLIANCE; PROTEIN EXPRESSION; PRURITUS; PUNCTATE KERATITIS; SQUAMOUS CELL METAPLASIA; TISSUE CULTURE; TREATMENT FAILURE;

EID: 14844288059     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(12)70120-9     Document Type: Article

References (63)

1. Wright KH.Textbook of ophthalmology. Baltimore, Williams and Wilkins, 1997,P 627
2. Quigley HA.Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389-93
3. Costagliola C, Prete AD, Incorvaia C, et al. Ocular surface alterations induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol 2001;239:809-14
4. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the effects of topical levobunolol timolol solution on the human ocular surface. Cornea 2003;22:709-15
5. Arici MK, Arici DS, Topalkara A, Guler C. Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exper Ophthalmol 2000;28:113-7
6. Shimazaki J, Hanada K, Yagi Y, Yamagami J, et al. Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomized study for the comparison of 0.5% timolol v 0.12% unoprostone. Br J Ophthalmol 200;84:1250-4
7. Yalvac IS, Gedikoglu G, Karagoz Y, Akgun U, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand 1995;73: 246-8
8. Campagna P, Macri A, Rolando M, Calabria G. Chronic topical eye preservative-free beta-blocker therapy effect on the ocular surface in glaucomatous patients. Acta Ophthalmol Scand Suppl 1997;(224):53
9. Herreras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alterations after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992;99:1082-8
10. Lass JH, Erikkson GL, Osterling L, Simpson CV, Latanoprost Corneal Effects Study Group. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked randomized, one-year study. Ophthalmology 2001;108:264-71
11. Kuppens E, Stolwijk T, van Best J, de Keizer R. Topical timolol, corneal epithelial permeability and autofluorescence in glaucoma by fluorophotometry. Graefes Arch Clin Exp Ophthalmol 1994;232:215-20
12. Niiya A, Yokoi N, Matsumoto Y, et al. Effect of beta-blocker on corneal epithelial barrier function. Ophthalmologica. 2000;214:332-6
13. Weissman SS, Asbell PA. Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity. Br J Ophthalmol 1990;74: 409-12
14. Buskirk EM. Adverse reactions from timolol administration. Ophthalmology 1980;87: 447-50
15. Sherwood M, Brandt J, Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45 suppl 4:S361-8
16. Stewart WC, Stewart JA, Day DG, et al. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. Eye 2004; 18:990-5
17. Higginbotham E, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs monotherapy. Arch Ophthalmol 2002;120:915-22
18. Stewart WC, Day DG, Sharpe ED, et al. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost. Am J Ophthalmol 1999;128:692-6
19. Stewart WC, Stewart JA, Day D, Sharpe ED. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonodone given twice daily. Acta Ophthalmologica Scand 2003;81:242-6
20. Pfeiffer N, European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002;240:893-9
21. Azuma I, Masuda K, Kytazawa Y, et al. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol 1993;37:514-25
22. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103:138-47
23. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996;103:1916-24
24. Alm A, Stjernschantz J. Effect on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandanavian Latanoprost Study. Ophthalmology 1995;102:1743-52
25. Bonomi L, Zavarise G, Noya E, Michieletto S. Effects of timolol maleate on tear flow in human eyes. Albrecht Von Graefes Arch Klin Exp Ophthalomol 1980;213:19-22
26. Haria M, Spencer CM. Unoprostone (isopropyl unoprostone). Drugs Aging 1996; 9:213-8. Erratum in Drugs Aging 1996;9:351).
27. Nelson J. Impression cytology. Cornea 1988; 7:71-81
28. Nelson JD, Havener VR, Cameron JD. Cellulose acetate impressions of the ocular surface in dry eye states. Arch Ophthalmol 1983;101:869-972
29. Abdel-Khalek LM, Williamson J, Lee WR. Morphological changes in the human epithelium. 1. In normal elderly population. Br J Ophthalmol 1978;62:792-9
30. Tseng SC, Hirst LW, Maumenee AE, et al. Possible mechanisms for the loss of goblet cells in mucin deficient disorders. Ophthalmology 1984;91:545-42
31. Brandt JD, Wittpenn JR, Katz LJ, et al. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol 1991;112:297-301
32. Turacli E, Budak K, Kaur A, et al. The effects of long-term topical glaucoma medications on conjunctival impression cytology. Int Ophthalmol 1997;21:27-33
33. Gerstenberger A, Marquardt R. [Goblet cell density modified by puilocarpine]. Fortschr Ophthalmol 1986;83:46-50
34. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol1994;112:1437-45
35. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology 1989;96: 327-35
36. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999;106: 556-63
37. Nuzzi R, Vercelli A, Finazzo C, Cracco C. Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: an immunohistochemical and ultrastructural study Graefes Arch Clin Exp Ophthalmol 1995;233:154-62
38. Baun O, Heegaard S, Kessing SV, Prause JU. The morphlology of conjunctiva after long-term topical antiglaucoma treatment. A quantitative analysis. Acta Ophthalmol Scand 1995;73:242-5
39. Baudouin C, Garcher C, Haouat N, et al. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 1994;101:454-60
40. Cvenkel B, Ihan A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica 2002; 216:175-9
41. Guglielminetti E, Barabino S, Monaco M, et al. HLA-DR expression in conjunctival cells after latanoprost. J Ocul Pharmacol Ther 2002;18:1-9
42. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004;45:1360-8
43. Bensoussan L, Blondin C, Baudouin C, et al. [Flow cytometric analysis of HLA-DR, IL-6 and IL-8 expression by conjunctival epithelial cells from patients with prolonged topical antiglaucoma treatments]. J Fr Ophtalmol 2003;26:782-9
44. Debbasch C, Pisella PJ, Rat P, et al. [Evaluation of free radical production by conjunctival impression cytology of patients treated with long-term antiglaucoma drugs or of contact lens wearers]. J Fr Ophtalmol 2000;23:239-44
45. Smith DL, Skuta GL, Kincaid MC, et al. The effects of glaucoma medications on Tenon's capsule and conjunctiva in the rabbit. Ophthalmic Surg 1991;22:336-40
46. Young TL, Higginbotham EJ, Zou XL, Farber MD. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology 1990;97:1423-7
47. Williams DE, Nguyen KD, Shapourifar-Tehrani S, et al. Effects of timolol, betaxolol, and levobunolol on human tenon's fibroblasts in tissue culture. Invest Ophthalmol Vis Sci 1992;33:2233-41
48. Toshino A, Okamoto S, Shimamura I, et al. [The mechanism of corneal epithelial disorder induced by prostaglandin F2 alpha isopropyl unoprostone]. Nippon Ganka Gakkai Zasshi. 1998;102:101-5
49. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18:205-15
50. Spickett C. Studies of cellular responses to purite and other preservatives. Strthclyde, UK: University of Strathclyde; 2001
51. Block SS. Disinfection, sterilization, and preservation. Malvern, PA,Lea & Febiger, 1991
52. Kreiner C. Biochemical aspects of ophthalmic preservatives. Contacto 1979; Nov:10-4
53. Grant WM, Schuman JS. Toxicology of the eye. Springfield, III, Charles C Thomas, 1990
54. Abelson M. How to handle BAK talk. Rev Ophthalmol 2002;9(12),Dec 15,2002
55. Levrat F, Pisella PJ, Baudouin C. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of unpublished survey in Europe]. J Fr Ophtalmol 1999;22:186-91
56. Pisella PJ, Pouliquen P, Daudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medications. Br J Ophthalmol 202;86;418-23
57. Nuzzi R, Finazzo C, Cerruti A. Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lacrymal (Brit. Engl) response. Int Ophthalmol 1998;22:31-5
58. De Saint Jean M, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved topical drugs in an in vitro model of conjunctival cells. Curr Eye Res 2000;20:85-94
59. Longstaff S, Wormald PR, Mazover A, Hitchings RA. Glaucoma triple procedures: efficacy of intraocular pressure control and visual outcome. Ophthalmic Surg 1990;21:786-93
60. Broadway D, Grierson I, Hitchings R. Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br J Ophthalmol 1993;77:590-96
61. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medications. II. The outcome of filtration surgery. Arch Ophthalmol 1994;112:1446-50
62. Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990;108:1543-8
63. Camras CB, Minckler D. Does that drug work? Pitfalls in studies on the efficacy and safety of glaucoma medications. Am J Ophthalmol 2000; 129:87-9